Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
– XCARTTM continuing to advance toward IND-enabling studies – PolyXen® platform technology growing royalty stream through license agreement – Closed the year with $18.2 million of cash Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient-